Grantees Not In Danger Of Losing Cost-Free Biological Materials, But Can’t Have Chemicals
In Brief: NCI Scientists May Run For Congress; Upton Back Heroin For Terminal Cancer Patients
R. Lee Clark to Retire; Texas Starts Search for Successor
Drugs Available To Investigators Centers to Monitor Them Are Listed
FDA’s Young Still Not Satisfied With Distribution Plan
Tobacco Council Announces Awards
FDA Adopts Final Diagnostics X-Ray Rule Amendment
Trending Stories
- Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - As daraxonrasib hits the clinic, Frank McCormick says RAS is bigger than pancreatic cancer
- From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma - The end of “more money, more people, more trials”
Cancer centers are being asked to grow their portfolios on flat budgets. Headcount is the wrong answer. - Letai takes a swipe at “ill-informed commentators,” as he lays out his scientific vision for NCI
“To my knowledge, 100% of grants that clear my desk get funded” - Harold Freeman, a surgeon who championed health equity, dies at 93
Freeman, the father of patient navigation, served as president of ACS and chair of the President’s Cancer Panel
